Cholestatic liver disease: pathophysiology and therapeutic options

被引:84
|
作者
Hofmann, AF [1 ]
机构
[1] Univ Calif San Diego, Dept Med, Div Gastroenterol, La Jolla, CA 92093 USA
来源
LIVER | 2002年 / 22卷
关键词
bile acids; cholestasis; extracorporeal albumin dialysis; haemoperfusion; pruritus; review;
D O I
10.1034/j.1600-0676.2002.00002.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Cholestasis results from defective canalicular secretion of bile or obstruction to bile flow distal to the canaliculus. In early primary biliary cirrhosis, bile secretion continues, because of the secretory pressure of bile or because some ductules are not obstructed. With complete cholestasis, a bile acid deficiency occurs in the small intestinal lumen leading to lipid maldigestion and fat-soluble vitamin malabsorption. Bacterial proliferation, bacterial translocation to lymph nodes and endotoxemia may also occur leading to an acute phase reaction. Retention of bile acids in the hepatocyte leads to apoptosis. Accumulation of bile acids in the systemic circulation leads to pruritus, and may contribute to endothelial injury in the lungs and kidney. Early attempts to mimic hepatic excretory function by hemoperfusion over adsorbent columns were unsuccessful for a variety of reasons. Extracorporeal dialysis against albumin offers promise of a realistic albeit partial simulation of hepatic excretory function.
引用
收藏
页码:14 / 19
页数:6
相关论文
共 50 条
  • [21] Pathophysiology and therapeutic options in osteogenesis imperfecta
    Semler, Oliver
    Kornak, Uwe
    Oheim, Ralf
    Seefried, Lothar
    OSTEOLOGIE, 2020, 29 (04) : 302 - 310
  • [22] Aortic aneurysm: pathophysiology and therapeutic options
    Yang, Guang
    Khan, Abbas
    Liang, Wei
    Xiong, Zibo
    Stegbauer, Johannes
    MEDCOMM, 2024, 5 (09):
  • [23] Cholestatic Liver Disease
    Juengst, Christoph
    Lammert, Frank
    DIGESTIVE DISEASES, 2013, 31 (01) : 152 - 154
  • [24] Cholestatic Liver Disease
    Gossard, Andrea A.
    Talwalkar, Jayant A.
    MEDICAL CLINICS OF NORTH AMERICA, 2014, 98 (01) : 73 - +
  • [25] URSODEOXYCHOLIC ACID - A NEW THERAPEUTIC APPROACH IN CHOLESTATIC LIVER-DISEASE
    RAEDSCH, R
    STIEHL, A
    KLINISCHE WOCHENSCHRIFT, 1989, 67 (04): : 265 - 268
  • [26] Nuclear Receptors CAR and PXR; therapeutic targets for cholestatic liver disease
    Kakizaki, Satoru
    Takizawa, Daichi
    Tojima, Hiroki
    Horiguchi, Norio
    Yamazaki, Yuichi
    Mori, Masatomo
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2011, 16 : 2988 - +
  • [27] Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents
    Sho Hasegawa
    Masato Yoneda
    Yusuke Kurita
    Asako Nogami
    Yasushi Honda
    Kunihiro Hosono
    Atsushi Nakajima
    Drugs, 2021, 81 : 1181 - 1192
  • [28] Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents
    Hasegawa, Sho
    Yoneda, Masato
    Kurita, Yusuke
    Nogami, Asako
    Honda, Yasushi
    Hosono, Kunihiro
    Nakajima, Atsushi
    DRUGS, 2021, 81 (10) : 1181 - 1192
  • [29] Notch signaling and new therapeutic options in liver disease
    Morell, Carola Maria
    Strazzabosco, Mario
    JOURNAL OF HEPATOLOGY, 2014, 60 (04) : 885 - 890
  • [30] FIBROGENESIS IN ALCOHOLIC LIVER DISEASE: POSSIBLE THERAPEUTIC OPTIONS
    Friedman, S.
    ALCOHOL AND ALCOHOLISM, 2011, 46 : 8 - 8